Computational Biology Department

Pioneer of Computational Biology Joins the Scientific Advisory Board of Predictive Oncology

Retrieved on: 
Thursday, January 12, 2023
National Health Council, Electricity, Institute of Electrical and Electronics Engineers, Computational Biology Department, Algorithm, American Institute, Doctor of Philosophy, Medicine, Biological engineering, Biomedical engineering, Machine learning, Biomarker, California Institute of Technology, Knowledge, Carnegie Mellon University, Professor, Electronics, Columbia University, Artificial intelligence, CORE, Patent, Research, Cancer, CMU, Columbia, American Institute for Medical and Biological Engineering, University of Freiburg, Probability, Medical imaging, Pharmaceutical industry, Biology, Biochemistry

He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform.

Key Points: 
  • He was founding head of the Computational Biology Department at Carnegie Mellon University (CMU), and led the development of CORE™, the machine learning technology that is exclusive to and powers Predictive Oncology’s PEDAL platform.
  • His experience with ground-breaking research is vital to the evolution of our predictive models and goal to discover more effective cancer therapies,” said Raymond F. Vennare, Predictive Oncology Chief Executive Officer and Chairman of the Board.
  • Predictive Oncology is changing the landscape of oncology drug discovery with a new category that goes beyond artificial intelligence.
  • In addition to his role as head of Computational Biology Department at CMU, Dr. Murphy has also served as Professor of Biological Sciences, Biomedical Engineering, and Machine Learning there.

Steakholder Foods® Shares Letter from the CEO, Arik Kaufman

Retrieved on: 
Tuesday, January 3, 2023
Happy New Year (2014 film), Security (finance), Annual report, Sustainable Development Goals, MITC, Carbon footprint, Intellectual property, Patent, United Nations Sustainable Development Group, Partnership, Meat, Marketing, FDA, Food security, Cell proliferation, Christmas and holiday season, USDA, Computational Biology Department, Water, Letter, 3D, Research, United Nations Global Compact, 3D printing, Risk management

REHOVOT, Israel, Jan. 3, 2023 /PRNewswire/ -- Steakholder Foods Ltd. (Nasdaq: STKH), (formerly MeaTech 3D: MITC), an international deep-tech food company at the forefront of the cultivated meat industry, shared a letter from the CEO, Arik Kaufman, highlighting the main achievements of 2022 and the accelerated go-to-market strategy for 2023.

Key Points: 
  • First and foremost, I would like to thank you for being a steakholder (as we like to say) in our company, mission, and community.
  • The purpose of this letter is to provide a general overview to the Steakholders' investor community about our achievements in 2022 and plans for 2023.
  • New risks and uncertainties may emerge from time to time, and it is not possible for Steakholder Foods to predict their occurrence or how they will affect Steakholder Foods.
  • Therefore, Steakholder Foods cautions you not to place undue reliance on its forward-looking information and statements.

Launch of collaboration to develop biodiversity indicators for Québec investors

Retrieved on: 
Thursday, December 8, 2022
Heart, The Wilderness Society, Bishop's University, McGill University, Sherbrooke, Learning, MONTRAL, CPAWS, Partnership, Biodiversity, CDPQ, Computational Biology Department, Research, Concordia University, Investment, Universitate metro station, Entrepreneurship, Growth, Saint Lawrence, Nature, Head, University, TELUQ, Climate change, CAD, Enrique Dussel, Organization, Pension fund, Agriculture, Management

Once created, they will allow a first in Canada: mobilizing players in conservation, biodiversity, research and finance to rally around protecting Qubec's biodiversity.

Key Points: 
  • Once created, they will allow a first in Canada: mobilizing players in conservation, biodiversity, research and finance to rally around protecting Qubec's biodiversity.
  • Investors represent a critical lever for quickly transforming the economy to reverse the loss of biodiversity.
  • The indicators created by this project will establish a shared framework to assess the impact investments have on biodiversity and improve decision-making.
  • "This unique project will provide shared indicators specific to Qubec that investors like CDPQ can leverage to have a positive impact on society and nature.

Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End

Retrieved on: 
Thursday, October 27, 2022
Diabetic retinopathy, Pharmacokinetics, ASH, SEQUOIA, Therapy, ESG, Company, Biotechnology, Drug discovery, R, CD40, Molecular Partners, Ranibizumab, DARPin, Pharmacology, General counsel, NASDAQ, CD70, Safety, Depreciation, Goal, CMO, D, Senior, Immunotherapy, Global, FAP, Novartis, DME, Program, Patient, Cell, CD33, CHF, Computational Biology Department, Antigen, NAMD, GLOBE, IFRS, CD123, CD3, FDA, Gene, AML, CET, Evaluation, SITC, Radiation, Renewable energy, Risk management, Online gambling, Pharmaceutical industry, Vaccine, Biology, CONCORD, Law

We have made notable progress this quarter across our oncology programs including MP0317, MP0533, as well as our DARPin-radioligand therapy programs.

Key Points: 
  • We have made notable progress this quarter across our oncology programs including MP0317, MP0533, as well as our DARPin-radioligand therapy programs.
  • We look forward to presenting the first clinical data from the MP0317 program for patients with solid tumors at SITC.
  • MP0533 engages CD3 on T cells while binding up to three tumor-associated antigens (CD33, CD70, and CD123) on AML cells.
  • Preclinical studies have shown that MP0533 T cell activation and tumor killing increased significantly with the number of tumor-associated antigens present.

Hillsdale College Hosts 170th Annual Commencement Ceremony, Welcomes Keynote Speaker Jordan B. Peterson

Retrieved on: 
Saturday, May 7, 2022
Parent, University, UCSB Physics Department, Church History Department, Death, Hillsdale College, Art department, Computational Biology Department, Partnership, Faculty, Family, Jordan, Friends, Life, Native Art Department International, Curriculum, Management, Medicine, Imprimis, College

HILLSDALE, Mich., May 7, 2022 /PRNewswire/ -- Hillsdale College celebrated its 170th Commencement on Saturday, May 7. The College has held this ceremony annually since 1860. Jordan B. Peterson, author, clinical psychologist, and professor emeritus at the University of Toronto, delivered the keynote address, and the College conferred honorary degrees and recognized top academic graduates.

Key Points: 
  • Jordan B. Peterson, author, clinical psychologist, and professor emeritus at the University of Toronto, delivered the keynote address, and the College conferred honorary degrees and recognized top academic graduates.
  • Larry P. Arnn, president of Hillsdale College, thanked the faculty, administration, parents, and friends of the College for making the ceremony possible.
  • He encouraged the graduating class to live out the things they learned while at Hillsdale.
  • Hillsdale College is an independent, nonsectarian, Christian liberal arts college located in southern Michigan.

Captor Therapeutics to Host R&D Day on May 18, 2022

Retrieved on: 
Thursday, May 5, 2022
University of Strasbourg, Drug development, AAP, EDT, University, Laboratory, Gastrointestinal disease, GLOBE, Liver disease, CTX, Cell, Viral, WSE, Cancer, Excellence, ERC, Cell Host & Microbe, Doctor of Philosophy, Funding of science, Hepatocellular carcinoma, Association, American Association, Degenerative disease, Therapy, Computational Biology Department, Patent, Virology, PNAS, Journal, MD, Research and development, R, Institute of Liver and Biliary Sciences, CEST, Center, Infection, HCC, TPD, European Research Council, Editing, American Association of Physician Specialists, Technology, Biology, Chronic liver disease, Pharmaceutical industry, Hepatology, Physician, Gastroenterology, Nature

Furthermore, he is the founder of Alentis Therapeutics, a Swiss/French biotech company developing novel therapeutics for fibrotic diseases and cancer.

Key Points: 
  • Furthermore, he is the founder of Alentis Therapeutics, a Swiss/French biotech company developing novel therapeutics for fibrotic diseases and cancer.
  • Captor Therapeutics is a biopharmaceutical company focused on leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough drug candidates in diseases with high unmet medical needs.
  • Captor is currently developing therapeutics for undertreated severe conditions, including malignancies and autoimmune diseases.
  • More information on Captor Therapeutics is available at: http://www.captortherapeutics.com

New testing device from March of Dimes Prematurity Research Center at Imperial College London allows for rapid detection of bacteria that identify risk for preterm birth

Retrieved on: 
Wednesday, October 13, 2021
University, Bethesda system, Gold, Resolution (mass spectrometry), HIV, NHS, Vagina, IVF, Technology, Reproduction, Twitter, Inflammation, Digestion, College, COVID-19, HPV, Imperial, Computational Biology Department, Nature Communications, Instagram, Woman, United Kingdom, Bacterial vaginosis, Kate, Infant, Medicine, Solution, Student, Bacteria, Reuters, Engineering, Multimedia, Metabolism, Hospital, Pregnancy, Death, Family, Color, Knowledge, Preterm birth, Cervical cerclage, View, Facebook, Risk, Virology, Department, Times Higher Education, Diagnosis, Industry, Education, Health, Institute, Cervical cancer, CEO, Patient, Science, Miscarriage, Research, Imperial College London, Birth control

ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth.

Key Points: 
  • ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth.
  • In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth.
  • March of Dimes, the infant and maternal health leader, is dedicated to advancing knowledge and solutions for preterm birth.
  • At Imperial College London, research is highlighting the important role of the reproductive tract microbiome in shaping preterm birth risk and other pregnancy outcomes.

New testing device from March of Dimes Prematurity Research Center at Imperial College London allows for rapid detection of bacteria that identify risk for preterm birth

Retrieved on: 
Wednesday, October 13, 2021
Twitter, Reproduction, Facebook, Inflammation, Technology, Digestion, Risk, Reuters, Virology, College, Pregnancy, Department, Engineering, COVID-19, University, HPV, Bethesda system, Gold, Times Higher Education, Imperial, Diagnosis, Resolution (mass spectrometry), HIV, Metabolism, Industry, Education, Nature Communications, Computational Biology Department, Instagram, Health, Hospital, Institute, Woman, United Kingdom, Bacterial vaginosis, NHS, Death, Family, Cervical cancer, Kate, Color, Infant, Knowledge, CEO, Medicine, Preterm birth, Solution, Vagina, Patient, Science, Student, Miscarriage, Research, IVF, Cervical cerclage, Bacteria, Imperial College London, Birth control

ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth. A study, published in Nature Communications, finds that the device can rapidly and accurately detect changes in vaginal bacteria and corresponding immune responses in pregnant women, which are associated with increased risk of preterm birth. This cost-effective test could facilitate faster clinical decision making and help improve targeted treatment strategies during pregnancy.

Key Points: 
  • ARLINGTON, Va., Oct. 13, 2021 /PRNewswire/ -- Researchers at the March of Dimes Prematurity Research Center at Imperial College London have developed a first-of-its-kind testing device that may help advance diagnosis and treatment of preterm birth.
  • In some women, certain bacteria from the microbiome can cause inflammation leading to an increased risk of preterm birth.
  • March of Dimes, the infant and maternal health leader, is dedicated to advancing knowledge and solutions for preterm birth.
  • At Imperial College London, research is highlighting the important role of the reproductive tract microbiome in shaping preterm birth risk and other pregnancy outcomes.

Dr. Sara Fletcher Harding Appointed New Dean Of Arts & Sciences At Florida Southern College

Retrieved on: 
Wednesday, October 6, 2021
STEM, U.S. News & World Report, Relationship between religion and science, Ben, Business, Growth, Learning, New Testament, The Princeton Review, Curriculum, School, Omicron Delta Kappa, Computational Biology Department, Multimedia, International Society, Leadership, UMC, Marquette University, The Science, Engineering & Technology Student of the Year Awards, College of Arts and Sciences, Humanities, Ministry, National Humanities Center, The arts, Religious studies, Student, AACSB, Nebraska Wesleyan University, Southern, Faculty, Jessie Ball duPont Fund, Florida Southern College, FSC, College, General Board of the United States Navy, Outline of health sciences, Dean, View, Research, NCAA Division III, Medicine

LAKELAND, Fla., Oct. 6, 2021 /PRNewswire/ --Florida Southern College (FSC) has appointed Dr. Sara Fletcher Harding as the new Dean of the School of Arts & Sciences, FSC's largest school.

Key Points: 
  • LAKELAND, Fla., Oct. 6, 2021 /PRNewswire/ --Florida Southern College (FSC) has appointed Dr. Sara Fletcher Harding as the new Dean of the School of Arts & Sciences, FSC's largest school.
  • "As a renowned interdisciplinary scholar of the sciences and religion, Dr. Harding blends the perspectives of the humanities and the sciences in her teaching and research.
  • As dean, she draws Florida Southern's arts and sciences faculty and students together by fostering an academic environment that encourages engaged, interdisciplinary learning."
  • Dr. Harding joined the faculty of Florida Southern College in 1997.

Auburn engineers create device that instantly reveals COVID test results

Retrieved on: 
Monday, September 13, 2021
Water, Knowledge, Biology, American Chemical Society, Physics, Quality of life, 3D, Antibody, SARS, 2D, Auburn University, Protein, Patient, Technology Center, Viral load, Alabama, Electronics, Solution, Nanotechnology, COVID-19, Multimedia, UCSB Physics Department, Virus, Computational Biology Department, Publishing, Hair, Research, Mercer University, Medical imaging, Pharmaceutical industry, Electronic component, Vaccine

AUBURN, Ala., Sept. 13, 2021 /PRNewswire/ --COVID-19 clinical test results are now available within hours, but can we do better?

Key Points: 
  • AUBURN, Ala., Sept. 13, 2021 /PRNewswire/ --COVID-19 clinical test results are now available within hours, but can we do better?
  • "When the virus spike protein interacts with the antibody within the testing device, it impacts the electronic properties of the atomically-thin monolayer 2D material.
  • As soon as the lab technician puts the sample drop on the transistor surface, the device responds, and the result is evident."
  • The promising results show potential toward the development of electronic biomedical sensors based on 2D materials fabricated using conventional semiconductor technologies.